Leg Cramps Pm Tablet, Soluble
NDC Package 54973-3093-2
Package Information
Leg Cramps Pm (oyster shell calcium carbonate, crude, causticum, matricaria recutita, cinchona officinalis bark, copper, lycopodium clavatum spore, magnesium phosphate, dibasic trihydrate, toxicodendron pubescens leaf, silicon dioxide, and sulfur) tablets is adults and children 12 years and older: Dissolve 2-3 tablets under tongue before bed to fall asleep, stay asleep and relieve leg cramps. This formulation utilizes a tablet, soluble delivery system. Marketed by Hyland's Inc., this product is identified by NDC 54973-3093.
Identification & Billing
Clinical Specifications
- CAUSTICUM 12 [hp_X]/1
- CINCHONA OFFICINALIS BARK 3 [hp_X]/1
- COPPER 12 [hp_X]/1
- LYCOPODIUM CLAVATUM SPORE 12 [hp_X]/1
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE 6 [hp_X]/1
- MATRICARIA RECUTITA 6 [hp_X]/1
- OYSTER SHELL CALCIUM CARBONATE, CRUDE 12 [hp_X]/1
- SILICON DIOXIDE 12 [hp_X]/1
- SULFUR 6 [hp_X]/1
- TOXICODENDRON PUBESCENS LEAF 6 [hp_X]/1
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Copper - [CS]
- Copper-containing Intrauterine Device - [EPC] (Established Pharmacologic Class)
- Decreased Embryonic Implantation - [PE] (Physiologic Effect)
- Decreased Sperm Motility - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibit Ovum Fertilization - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 54973 - Hyland's Inc.
- 54973-3093 - Leg Cramps Pm
- 54973-3093-2 - 1 BOTTLE in 1 CARTON / 30 TABLET, SOLUBLE in 1 BOTTLE
- 54973-3093 - Leg Cramps Pm
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (54973-3093). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 54973-3093-2 identifies a specific commercial package of 1 bottle in 1 carton / 30 tablet, soluble in 1 bottle of Leg Cramps Pm, a human over the counter drug labeled by Hyland's Inc.. This tablet, soluble is formulated for oral use and contains causticum; cinchona officinalis bark; copper; lycopodium clavatum spore; magnesium phosphate, dibasic trihydrate; matricaria recutita; oyster shell calcium carbonate, crude; silicon dioxide; sulfur; toxicodendron pubescens leaf as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hyland's Inc. on January 01, 2010. The current certification is valid through December 31, 2026.
How is this Hyland's Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 54973309302. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.